One FIP
United for a healthier world

International Pharmaceutical Federation
Annual report 2022
# Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreword from the FIP president</td>
<td>2</td>
</tr>
<tr>
<td>Snapshots 2022</td>
<td>3</td>
</tr>
<tr>
<td>About FIP</td>
<td>7</td>
</tr>
<tr>
<td>Our members — The global pharmacy family in 2022</td>
<td>9</td>
</tr>
<tr>
<td>Member engagement</td>
<td>11</td>
</tr>
<tr>
<td>Primary health care — Acting on our commitment</td>
<td>12</td>
</tr>
<tr>
<td>FIP Development Goals 2022: The second year in a decade of action</td>
<td>13</td>
</tr>
<tr>
<td>Focus on our profession and practice</td>
<td>15</td>
</tr>
<tr>
<td>Health benefits for patients and communities</td>
<td>17</td>
</tr>
<tr>
<td>Transforming education and workforce</td>
<td>19</td>
</tr>
<tr>
<td>Collaborations and partnerships</td>
<td>21</td>
</tr>
<tr>
<td>World Pharmacists Day and World Pharmacy Week 2022</td>
<td>23</td>
</tr>
<tr>
<td>Recognising excellence through FIP Awards</td>
<td>25</td>
</tr>
<tr>
<td>Council decisions</td>
<td>27</td>
</tr>
<tr>
<td>80th World Congress of Pharmacy and Pharmaceutical Sciences</td>
<td>29</td>
</tr>
<tr>
<td>FIP Digital Events</td>
<td>30</td>
</tr>
<tr>
<td>Bureau members completing their terms</td>
<td>31</td>
</tr>
<tr>
<td>Publications</td>
<td>33</td>
</tr>
<tr>
<td>Work in progress</td>
<td>38</td>
</tr>
<tr>
<td>Finances</td>
<td>39</td>
</tr>
</tbody>
</table>
It is my pleasure to welcome you to this annual report giving an overview of the activities of FIP. 2022 was a very busy year. Considering global developments and challenges which, sadly, included lives lost in natural disasters and wars, I am very proud of the work done with and by our member organisations and our individual members. FIP has continued to support them with resources such as reports and webinars, and advocacy activities, all guided by the FIP Development Goals (see p13), which give a common direction to the profession for its evolution around the world for the ultimate benefit of our communities.

Although COVID-19 remains a public health emergency of international concern, we have learned to manage it, adapting our lives, work and services. It is thanks to our profession that vaccination coverage has grown. As a result, I was delighted that, finally, our FIP family was able to meet again, face to face, at our 80th World Congress of Pharmacy and Pharmaceutical Sciences in September. In Seville, Spain, we stood united for a healthier world (see p25). During this congress, attended by colleagues from 100 countries, much learning from COVID-19 and work on pandemic preparedness was shared. Through our collective efforts — and with FIP at the centre — we now have good evidence to reflect on and use to transform our profession globally so that it is fully equipped to contribute to present and future challenges facing our health systems.

In 2022, World Health Organization director general Tedros Adhanom Ghebreyesus described “5 Ps” as priorities needed to accelerate progress towards the Triple Billion Targets and the Sustainable Development Goals: Promoting, Providing, Protecting, Powering and Performing for health.

I add a sixth P — Pharmacy!

Around the world, pharmacists, pharmaceutical scientists and pharmacy educators are taking all these actions. Pharmacy can provide solutions to many of the health challenges we face. For example, we are essential to primary health care provision and, therefore, to universal health coverage. Enhancing the roles of pharmacists in this arena is a FIP priority (see p12).

FIP is supporting global health, supporting our profession, and supporting our members in their work. FIP has worked hard for pharmacy throughout 2022 and will continue to do so. I want to thank everybody who is active in FIP for their time, their competences and their dedication, thanks to which we benefit from the experiences of each other. As One FIP, and in trust and solidarity, we can transform our dreams into actions.

I am looking forward to collaborating with you further this year and making the 21st century the century of pharmacists.

Long live pharmacy!
Long live FIP!

Dominique Jordan
President, International Pharmaceutical Federation (FIP)
WHO renews official relations with FIP

FIP’s status as a non-governmental organisation in official relations with the World Health Organization (WHO) was successfully renewed at the start of 2022. The WHO assesses its collaboration with FIP every three years, based on joint work delivered and areas for future collaboration and mutual benefit for patient care and public health. FIP and the WHO have been in official relations for 75 years. FIP’s official status with the WHO means that the federation is in a unique position to advocate pharmacists’, pharmaceutical scientists’ and pharmacy educators’ roles in the global health agenda. Under this relationship, and supplemented by a memorandum of understanding in 2019, FIP and the WHO work together on a number of projects, including, in 2022, a course supporting educators to ensure that pharmacists are better able to prevent substandard or falsified medicines from reaching patients (see p20). “Ongoing collaboration with the WHO and alignment of collaborative workstreams is strategically important,” said FIP CEO Catherine Duggan.

WHO's status with the WHO gives pharmacy a voice at meetings of WHO governing bodies

Quarter 2: April to June

Pharmaceutical data made more accessible

June saw the launch of the FIP Global Pharmaceutical Observatory (GPO) microsite, which allows easy viewing of the federation’s work in the area of pharmaceutical intelligence. The GPO collates and validates global data on pharmacy workforce, practice and pharmaceutical science. Under the GPO, FIP undertakes comprehensive analyses and provides accessible, high-quality intelligence that supports member organisations in their work, particularly in relation to advocacy. Through the new microsite, data and intelligence are visualised via the GPO Atlas. The work of the GPO includes multinational needs assessment programmes (launched in 2022) to identify priorities around digital health supporting national pharmaceutical care delivery and to identify future plans needed in advocating and supporting pharmacists’ roles (e.g., in anaemia and vaccination). The digital health programme included six regional events at which countries discussed the needs and challenges pharmaceutical leadership bodies face in using digital health to support medication adherence and combat substandard and falsified medicines, as well as opportunities and initiatives.
Quarter 3: July to September

FIP president urges Spanish politicians to work with pharmacists

Pharmacy is vital to universal health coverage, FIP president Dominique Jordan told politicians at a meeting at the Parliament of Andalusia in Seville, Spain, in September. Addressing officials at an event organised by FIP member organisation the General Pharmaceutical Council of Spain in advance of World Pharmacists Day, Mr Jordan said that pharmacists and pharmacies are integral to a well-functioning healthcare system.

“I would like to make known that the pharmacy profession across the globe is committed to and united in action for a healthier world,” he added. During the meeting, the General Pharmaceutical Council officially declared its joining FIP’s World Pharmacists Day campaign.

Education celebrates two milestones

FIP’s Academic Pharmacy Section (AcPS) celebrated half a century of working to advance pharmacy education worldwide during the FIP congress in Seville, Spain, in September. “I believe the next 50 years will see a concerted effort among our colleague academics and academic leaders to connect and collaborate to advance education in science and practice while advocating education policies that impact our profession,” said AcPS president Toyin Tofade. To mark the anniversary, the Pharmacy Education journal (PEJ) published a special issue, with 23 articles from the section’s members on the advancement of pharmacy education worldwide and active projects and history of the AcPS. In 2022, the PEJ itself celebrated its 40th anniversary. Pharmacy Education publishes peer-reviewed manuscripts in the practice domain of pharmacy education (at all stages) and workforce development research and evaluation. “The journal is planning to widen its scope by introducing educationally related short, rapid response articles targeting non-traditional authors (for example, non-academics) in practice and science sectors,” said PEJ editor Marwan El Akel.

Quarter 4: October to December

Working together to reduce antimicrobial resistance

At the start of World Antimicrobial Awareness Week 2022, FIP published a new Commitment on Antimicrobial Resistance (AMR). This describes the number of ways by which the federation will increase awareness of AMR, strengthen antimicrobial stewardship (AMS) and support evidence-based interventions. Among these are supporting scientific research, collaborating to develop wider strategies to rationalise antimicrobial consumption, and leveraging channels of communication. The commitment is inclusive of education, practice, scientific research and workforce development and works across nations and regions. “All parts of pharmacy have a role to play in this issue. This One FIP commitment is significant in uniting different sectors on AMR for a healthier world, outlining specific actions that can be taken forward,” said Manjiri Gharat, chair, FIP AMR Commission. The FIP AMR Commission was established in 2020 to drive FIP’s efforts to facilitate the essential contributions of the pharmacy profession to AMR reduction around the world, including through surveillance and monitoring of antimicrobial use and resistance, responsible antibiotics distribution, and regulation.

Regulators encouraged to enable pharmacy care for NCDs

Regulators, ministries of health, policymakers and national pharmacy organisations were encouraged to assess regulations in their country related to pharmacy-based care of non-communicable diseases (NCDs) through a new FIP development tool in November. The tool was developed by experts from the FIP Regulators Advisory Group. It is based on their experiences from countries where pharmacy services targeting NCDs (including testing, measurement of parameters, such as blood pressure, and prescribing) have been successfully introduced and regulated, and on legislation around the world. “This resource provides an excellent template to assess the status of pharmacy practice regarding NCDs as well as being an invaluable tool for countries that currently do not have pharmacists involved in an expanded scope in this area,” said Ronald Guse, chair of the FIP Regulators Advisory Group. (See p15 for more on NCDs.) “This is great work, very clear and easy to understand. This will provide a very good guide for regulators,” said Andi Shirtcliffe, clinical chief advisor, Pharmacy & Allied Health Office of the Chief Clinical Officers, Ministry of Health, New Zealand.

New FIP CPD Bites focus on ethical dilemmas in practice

In December, FIP launched a new format of continuing professional development. FIP CPD Bites “FIP already offers numerous resources to support the profession with CPD, including webinars, digital events, congress sessions and publications such as handbooks and knowledge and skills guides. However, we understand that many have different learning styles and preferences, and time. The growing demands on pharmacists’ time means that there is a need for concise, engaging, evidence-driven and easily accessible learning materials. FIP CPD Bites aims to meet this need through short videos with role-plays, analysis and advice,” explained Dalja Bajic, FIP lead for provision and partnerships. The first series of CPD Bites comprises seven videos that present a decision-making framework and its application to help pharmacists deal with different ethical dilemmas in pharmacy practice. “To enable better understanding of our obligations, these CPD Bites offer real-life examples in role-play, accompanied by clear, simply articulated analyses and recommended actions to help colleagues make professionally justifiable ethical decisions,” said Betty Chaar, chair, FIP Working Group on Ethics.

New FIP resource supports care of cancer, cardiovascular diseases, chronic respiratory diseases, diabetes and mental health
About FIP*

Who we are

The International Pharmaceutical Federation (FIP) is the global federation of national associations of pharmacists and pharmaceutical scientists, with (at the time of publication) 152 member organisations, of which 11 are predominantly scientific organisations, and 177 academic institutional members.

FIP is a non-governmental organisation that has been in official relations with the World Health Organization since 1948. FIP is a founder member and one of five health professional organisations that form the World Health Professions Alliance (WHPA). Bringing together medicine, nursing, dentistry, physical therapy and pharmacy, the WHPA represents more than 42 million healthcare professionals.

What we do

FIP’s vision is a world where everyone benefits from access to safe, effective, quality and affordable medicines and health technologies, as well as from pharmaceutical care services provided by pharmacists, in collaboration with other healthcare professionals.

Our mission is to support global health by enabling the advancement of pharmaceutical practice, sciences and education. This mission is articulated to members and key stakeholders through FIP’s Strategic Plan 2019–2024.

“A world where everyone benefits from access to safe, effective, quality and affordable medicines and health technologies.”

How we work

FIP’s activities can be divided into three main areas — science, practice and education (and workforce) — although these areas are working increasingly more closely as “One FIP”. FIP regional forums, FIP advisory groups (e.g. on technology and for regulators) and FIP commissions (on antimicrobial resistance and data and intelligence) cut across all three areas to influence our One FIP thinking and gather ideas and projects. The FIP Consortium advises on

the FIP Seal for continuing professional development programmes and accreditation agencies (see p12) and criteria developed to ensure the quality of FIP-developed provision. In addition, the FIP Hub supports continued implementation of the 21 FIP Development Goals (see p3).

Science

Work to advance the pharmaceutical sciences globally is primarily done through six special interest groups (SIGs) led by the Board of Pharmaceutical Sciences. There are SIGs for:

- Drug delivery and manufacturing
- New generation of pharmaceutical scientists
- New medicines
- Personalised and precision medicine
- Pharmacy practice research
- Regulatory sciences and quality

Practice

A priority for FIP is to advance pharmacy practice in all settings, and this is led through the projects and initiatives of eight pharmacy practice sections (led by the Board of Pharmaceutical Practice). There are sections for:

- Academic pharmacy
- Clinical biology
- Community pharmacy
- Health and medicines information
- Hospital pharmacy
- Industrial pharmacy
- Military and emergency pharmacy
- Social and administrative pharmacy

Education

The reform of pharmacy education in the context of pharmaceutical workforce development is a third objective, and this is the purpose of FIP Education (FIPEd), which includes:

- Academic Pharmacy Section members (Faculty members and educators)
- Academic institutional members (heads of schools of pharmacy and pharmaceutical sciences)
- A Pharmacy Technicians and Support Workforce Strategic Platform and its advisory committee; and
- The FIP-UNESCO UNITWIN programme (regional university networks to advance pharmaceutical education), which is a global partnership between FIP and UNESCO.

“As ‘One FIP’, science, practice and education are taking action together.”

The FIP Bureau

FIP directs particular efforts towards early career pharmacists and the preparation of congresses through its Early Career Pharmaceutical Group and Congress Programme Development Group, respectively. In addition, among the boards, sections, SIGs, commissions, advisory groups and regional forums described above are ad hoc working and focus groups. FIP is governed by the FIP Council and the FIP Bureau (the organisation’s governing board). The Council is comprised of representatives of our member organisations, Bureau members and section presidents. Our observer organisations participate in the Council but may not vote. Vice presidents are elected from the Council to make up the Bureau. A president is elected to chair the Bureau and preside over FIP for a four-year term. The Bureau consists of 24 elected officers (plus the FIP chief executive officer, ex officio) as follows:

President
Mr Dominique Jordan (Switzerland)

Chief executive officer
Mr Paul Sinclair (Australia)

Chair of the Board of Pharmaceutical Practice
Mr Daragh Connolly (Ireland)

Vice president
Prof. Parisa Aslani (Australia)

President elect
Mr Ralph Altiere (USA)

Scientific secretary
Prof. Giovanni Pauletti (USA)

Vice president
Ms Manjiri Sandeep Gharat (India)

Professional secretary
Prof. Ralph Altiere (USA)

Vice president
Dr Prosper Hiag (Cameroon)

Chair of FIP Education
Prof. Ralph Altiere (USA)

Chair of the Board of Pharmaceutical Sciences
Prof. Giovanni Pauletti (Australia)

Vice president
Mr Daragh Connolly (Ireland)

Vice president
Ms Manjiri Sandeep Gharat (India)

** As May 2023

** In 2022, the FIP Council unanimously accepted integration of the regional pharmaceutical forums into FIP in 2023.

FIP’s day-to-day activities are managed by an executive committee and a team of staff at our headquarters in the Netherlands and across the world, supported by an extensive global pharmacy and pharmaceutical sciences network and our partnerships. Individual annual reports of the SIGs and sections are available at www.fip.org.

* As May 2023

** In 2022, the FIP Council unanimously accepted integration of the regional pharmaceutical forums into FIP in 2023.
Our members — The global pharmacy family in 2022

Through our membership, FIP has presence in 154 countries and territories, representing around four million pharmacists, pharmaceutical scientists and pharmacy educators.

FIP membership for 2022 was as follows:

- **153** Member organisations
- **172** Academic institutional members
- **24** Observer organisations
- **4,069** Individual members

*Full lists of FIP member organisations, observer organisations and academic institutional members can be found at: [https://www.fip.org/member-organisations](https://www.fip.org/member-organisations)

New member organisations

At its meetings in September and December 2022, the FIP Council admitted the following as member organisations:

- Caribbean Association of Pharmacists (Jamaica)
- Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas (USA)
- Pharmacists Defence Association (UK)
- Pharmaceutical Society of Malawi
- Royal Pharmaceutical Society (GB [readmission])
- Saudi Pharmaceutical Society (Saudi Arabia)
- Saudi Society of Clinical Pharmacy (Saudi Arabia)
- Syndicate of Kurdistan Pharmacists (Iraq)

"We joined FIP to seek out the very best ideas from a much larger international network for the benefit of our members. Through participation in FIP activity, we and our individual members not only get to learn from international colleagues, we have the chance to contribute to the international conversation about pharmacy too. The collective views of individual pharmacists can also pass through FIP to international discussions and ultimately to the World Health Organization, if appropriate."

Mr Mark Koziol
Chairman, Pharmacists Defence Association (UK)

New observer organisations

At its meeting in September 2022, the FIP Council admitted the following two new observer organisations:

- Federation of Cooperative Pharmacists of Greece
- Pharmacy Association of Lesotho

New academic institutional members

FIP welcomed the following schools of pharmacy to academic institutional membership (AIM) in 2022:

- University of South Australia (Australia)
- Medical University of Plovdiv (Bulgaria)
- University of Ottawa (Canada)
- Frederick University (Cyprus)
- University of Pécs (Hungary)
- Republic of Indonesia Defense University (Indonesia)
- American University of Iraq - Baghdad (Iraq)
- Vilnius University (Lithuania)
- AI-Quds University (Occupied Palestinian Territory)
- An-Najah National University (Occupied Palestinian Territory)
- University of Kragujevac (Serbia)
- University of Niš (Serbia)
- University of Veterinary Medicine and Pharmacy in Kosice (Slovak Republic)
- Granada University (Spain)
- San Pablo CEU (Spain)
- Idlib University (Syrian Arab Republic)
- University of Wolverhampton (UK)
- Albany College of Pharmacy and Health Sciences (USA)
- University of Connecticut (USA)
- St. John's University (USA)

"The mission of the Faculty of Pharmacy at Al-Quds University is to educate students to provide pharmaceutical care, to promote research and scholarly activities in the pharmaceutical sciences, and to serve as a pharmacy resource for Palestinian society and others around the world. Through our membership with FIP, we seek to expand our professional and scientific network, keep updated in pharmacy practices, and exchange academic experiences in teaching, curriculum development and international accreditation."

Prof. Ahmad Amro
Dean, Al-Quds University (Occupied Palestinian Territory)

"It is always good to collaborate with others in the profession, more so in these times when things are changing so rapidly. Information and technology are evolving so fast in most sectors. The Pharmaceutical Society of Malawi hopes that FIP will accord it the opportunity to keep pace with innovations in the pharmaceutical sector as they occur."

Mr William Mpute
President, Pharmaceutical Society of Malawi

"The Saudi Society of Clinical Pharmacy aims to provide scientific guidance, recommendations and insights for clinical pharmacists, and to improve the clinical pharmacy profession at national and international levels. Working alongside FIP, we believe we could achieve this mission."

Prof. Ahmed Aljedai
President, Saudi Society of Clinical Pharmacy (Saudi Arabia)
Member engagement

Through strategies to consult and engage, FIP strengthens relationships to ensure the advancement of pharmacy and health care in all parts of the world. Many engagement opportunities and meetings took place in 2022. A series of four regional engagement meetings focusing on member organisation engagement were held in June 2022. At each meeting, based on member organisation requests, the recognition of pharmacists as service providers and expanding their role and the role of pharmacists in non-communicable and chronic diseases were discussed. Between January and November 2022, FIP also had 35 formal one-to-one meetings with member organisations. These aimed to enhance collaboration, strategise specific actions and coordinate joint efforts to address needs.

Engaging on membership

FIP has undertaken consultations to propose and finalise work related to membership categories, fees and voting. Following the Council meeting in Seville, four consultation meetings — for member and observer organisations, for academic institutional members, for FIP sections, and for the Board of Pharmaceutical Sciences — were organised in quarter 4, 2022. Members who had further reflections or detailed feedback were asked to complete a survey. FIP also offered Council members the opportunity to meet on a one-to-one basis to discuss any concerns.

FIP marked the fourth anniversary of the Astana Declaration (see Box) in October 2022 by showcasing 50 initiatives from 27 countries demonstrating actions that pharmacists are taking to progress primary health care provision. These initiatives can be found on the first edition of the FIP Primary Health Care World Map. The map was developed in alignment with the WHO-UNICEF “Primary Health Care Measurement Framework and Indicators” to track and monitor progress in strengthening primary health care-oriented health systems as accelerators towards universal health coverage and the Sustainable Development Goals. In addition, two workshops involving the FIP Community Pharmacy Section executive committee and the FIP Global Pharmaceutical Observatory team prioritised the WHO-UNICEF indicators that can be used to report pharmacy’s progress by the next anniversary of FIP’s commitment to the declaration. The 50 good practice examples so far include an “entire life service” for chronic obstructive pulmonary disease in China, continuing professional development for the provision of primary health care in South Africa, and mental health support services in Australia.

FIP’s actions since 2018 have built on the principles of the declaration through three key programmes of work, namely, the FIP Astana imperative areas of non-communicable diseases (see p3), prevention (see p21) and patient safety (see p4). At the World Health Organization World Patient Safety Day Global Virtual Event in September 2022, FIP was an invited speaker and advocated the role of pharmacists in reducing medication errors and medication-related harm.

FIP Champions Programme

In 2022, the FIP Champions Programme, overseen by Mahendra Patel (UK) and Lars-Åke Söderlund (Sweden), was launched. The aim of this programme is to promote One FIP benefits and messages, and to engage with countries where FIP does not yet have members. Fifty FIP champions from 25 countries were selected to share their experiences of and evaluate the value of FIP membership benefits.

“I am proud to be a member of the FIP family because FIP is the oldest, most established and respected international pharmaceutical organisation that works in the interests of both pharmacists and pharmacy organisations. I support the work of FIP because of its high relevance and timeliness to help practising pharmacists (as they) respond to issues and challenges they face in undertaking their role to the highest standards. Being an FIP champion will allow me to actively contribute to continuous efforts to support pharmacists all over the world and raise their awareness of the tools available from FIP to help advance their role and contribution to their healthcare systems.”

Dr Dalia Dawoud
FIP champion (UK)

“I am proud to be a member of the FIP family because my association with the federation has given me personal and professional trajectories. For example, I was among the set of FIP Young Pharmacist Group [Early Career Pharmaceutical Group] members to be on the FIP delegation to the 72nd World Health Assembly in May 2019. This was a first-hand experience that enabled me to understand some technical and practical work of FIP, the WHO and various health professional associations across the globe. I serve FIP in various committees and these roles impact positively in many aspects of my career. They have helped improve my communication and critical thinking skills and developed my network of professional colleagues.”

Dr Garba Mohammed Khalid
FIP champion (Nigeria)

There are 50 FIP champions from 25 countries.

Primary health care — Acting on our commitment

A series of four regional engagement meetings focusing on non-communicable and chronic diseases were discussed. Between January and November 2022, FIP also had 35 formal one-to-one meetings with member organisations. These aimed to enhance collaboration, strategise specific actions and coordinate joint efforts to address needs.

Primary health care — Acting on our commitment

FIP has undertaken consultations to propose and finalise work related to membership categories, fees and voting. Following the Council meeting in Seville, four consultation meetings — for member and observer organisations, for academic institutional members, for FIP sections, and for the Board of Pharmaceutical Sciences — were organised in quarter 4, 2022. Members who had further reflections or detailed feedback were asked to complete a survey. FIP also offered Council members the opportunity to meet on a one-to-one basis to discuss any concerns.

FIP has undertaken consultations to propose and finalise work related to membership categories, fees and voting. Following the Council meeting in Seville, four consultation meetings — for member and observer organisations, for academic institutional members, for FIP sections, and for the Board of Pharmaceutical Sciences — were organised in quarter 4, 2022. Members who had further reflections or detailed feedback were asked to complete a survey. FIP also offered Council members the opportunity to meet on a one-to-one basis to discuss any concerns.

“I am proud to be a member of the FIP family because FIP is the oldest, most established and respected international pharmaceutical organisation that works in the interests of both pharmacists and pharmacy organisations. I support the work of FIP because of its high relevance and timeliness to help practising pharmacists (as they) respond to issues and challenges they face in undertaking their role to the highest standards. Being an FIP champion will allow me to actively contribute to continuous efforts to support pharmacists all over the world and raise their awareness of the tools available from FIP to help advance their role and contribution to their healthcare systems.”

Dr Dalia Dawoud
FIP champion (UK)

“I am proud to be a member of the FIP family because my association with the federation has given me personal and professional trajectories. For example, I was among the set of FIP Young Pharmacist Group [Early Career Pharmaceutical Group] members to be on the FIP delegation to the 72nd World Health Assembly in May 2019. This was a first-hand experience that enabled me to understand some technical and practical work of FIP, the WHO and various health professional associations across the globe. I serve FIP in various committees and these roles impact positively in many aspects of my career. They have helped improve my communication and critical thinking skills and developed my network of professional colleagues.”

Dr Garba Mohammed Khalid
FIP champion (Nigeria)

There are 50 FIP champions from 25 countries.

Astana Declaration and FIP

In 2018, the world came together at the Global Conference on Primary Health Care in Nur-Sultan (previously Astana), Kazakhstan, where heads of state and government and ministers pledged to recommit to strengthening primary health care to achieve universal health coverage and the United Nations Sustainable Development Goals in the Declaration of Astana. The conference took place on the 40th anniversary of the Declaration of Alma-Ata, a major milestone in public health which identified primary health care as key to health for all.

FIP was part of the global community in Nur-Sultan that renewed political focus on primary health care at this historic meeting, contributing to and signing the declaration. Since that time, the federation has worked to strengthen pharmacy’s contributions to, and impact on, primary health care, with events to garner commitment from the profession and action to advance pharmacists’ roles, such as the strategic decision to create the FIP Hub (see p14).
FIP Development Goals 2022: The second year in a decade of action

The 21 FIP Development Goals, published in 2020, bring together workforce and education, practice and science under a transformative framework, and define an improved and more advanced pharmacy profession for the next decade in alignment with FIP’s mission and with wider global imperatives such as the United Nations Sustainable Development Goals. Having a set of “One FIP” development goals provides a consistent way to identify commonalities across FIP, as well as enabling needs assessment and mapping of priorities. For example, the FIP Development Goals have been mapped with key FIP programmes in non-communicable diseases, prevention and patient safety for universal health coverage through primary health care.

The FIP Development Goals are accompanied by a growing set of global tools, structures, and programmes to facilitate and support the process of transformation. In 2022, the FIP Development Goals, with the intent of driving further alignment of the work of the HPS with these goals,” said HPS president Ryan Forrey. Welcoming the new HPS Strategic Plan 2022 creates a cross walk between the Basel Statements and the FIP Development Goals, retaining workforce development elements of the WDH and bringing in the elements of pharmaceutical practice and science. It will be channelled with the wider FIP missions that are aligned with universal health coverage and the Astana Declaration on primary health care. A transition from the WDH to the new FIP Hub is planned over three six-month phases with clear outcomes set. A special reception was at the FIP congress in September to officially announce the new FIP Hub, and to celebrate the legacy it builds on over more than 10 years. “The wider FIP Hub now being implemented will extend our development work with global experts on professional pharmacy imperatives that align with specific development goals, while we are excited about implementing this new structure to support our members across education, science and practice. The new FIP Hub will continue to accelerate the global advancement of pharmacy through the FIP mission,” said Ian Bates, WDH director.

In July, joint work by the Commonwealth Pharmacists Association and FIP culminated in the publication of a comparative analysis of pharmaceutical workforce development needs across the Commonwealth in Research in Social and Administrative Pharmacy.

This work identified policy directions and factors affecting pharmacy workforce development across the Commonwealth and examined country progress made towards implementing workforce-oriented FIP Development Goals.

September 2022 saw the publication of “The FIP global roadmap 2030: Sustainable advancement for pharmacy worldwide”, which summarises a FIP Bureau Insights Board meeting held in July 2022 and describes significant milestones that FIP aspires to achieve on the road to 2030.

Transforming pharmacy as One FIP

Different constituents of FIP are aligning their strategies to join the transformation journey. For example, following member consultation and deliberative meetings, November saw the publication of a new strategic plan (2022–27) by FIP’s Hospital Pharmacy Section (HPS). “Since 2008, the HPS Basel Statements on the Future of Hospital Pharmacy have been the guiding light for the work of our section and our members. The new HPS Strategic Plan 2022 creates a cross walk between the Basel Statements and the FIP Development Goals, retaining workforce development elements of the WDH and bringing in the elements of pharmaceutical practice and science. It will be channelled with the wider FIP missions that are aligned with universal health coverage and the Astana Declaration on primary health care. A transition from the WDH to the new FIP Hub is planned over three six-month phases with clear outcomes set. A special reception was at the FIP congress in September to officially announce the new FIP Hub, and to celebrate the legacy it builds on over more than 10 years. “The wider FIP Hub now being implemented will extend our development work with global experts on professional pharmacy imperatives that align with specific development goals, while we are excited about implementing this new structure to support our members across education, science and practice. The new FIP Hub will continue to accelerate the global advancement of pharmacy through the FIP mission,” said Ian Bates, WDH director.

FIP Hub

Following wide consultations around increased alignment with global health agendas, in 2022 the FIP Bureau agreed to extend the successes of the FIP Education Workforce Development Hub (WDH) and establish a broader hub to cover FIP. This new “FIP Hub” will support continued implementation of the FIP Development Goals, retaining workforce development elements of the WDH and bringing in the elements of pharmaceutical practice and science. It will be channelled with the wider FIP missions that are aligned with universal health coverage and the Astana Declaration on primary health care. A transition from the WDH to the new FIP Hub is planned over three six-month phases with clear outcomes set. A special reception was at the FIP congress in September to officially announce the new FIP Hub, and to celebrate the legacy it builds on over more than 10 years. “The wider FIP Hub now being implemented will extend our development work with global experts on professional pharmacy imperatives that align with specific development goals, while we are excited about implementing this new structure to support our members across education, science and practice. The new FIP Hub will continue to accelerate the global advancement of pharmacy through the FIP mission,” said Ian Bates, WDH director.

FIP is working to make the FIP Development Goals available in as many languages as possible. A translation in Portuguese was published in February, thanks to the Association of Pharmacists of Portuguese-Speaking Countries. A Serbian translation was launched, thanks to the Pharmaceutical Chamber of Serbia and the University of Belgrade Faculty of Pharmacy, at the 8th Congress of Pharmacists of Serbia in October.
Focus on our profession and practice

Tackling energy shortages in Africa

 Nearly 60% of healthcare facilities in sub-Saharan Africa have no access to electricity and in many places supplies through national networks regularly fail to keep pace with demand, with power outages experienced as much as 50% of the time. According to the World Economic Forum, almost half of all vaccines are wasted because approximately 50% of refrigerators used in clinics have no reliable electricity supply. This serious issue was raised by the African Pharmaceutical Forum (APF) during FIP’s regional engagement meetings in 2021 and FIP subsequently wrote to energy suppliers across Africa asking for collaboration. As a result, FIP and the APF met with a syndicate of renewable energy suppliers early in 2022 to give our profession’s expert insight on needs and the risk to lives created by unreliable energy supplies, and to work on solutions such as innovative and sustainable business models. FIP will be supporting a factsheet developed by the syndicate for its members and looks forward to this stimulating greater action within the energy sector.

FIP continued to take work in this area forward in 2022 through other channels, with Didier Mouliom, FIP Industrial Pharmacy Section vice president, giving a presentation developed by the syndicate for its members and looks forward to this stimulating greater action within the energy sector. FIP continued to take work in this area forward in 2022 through other channels, with Didier Mouliom, FIP Industrial Pharmacy Section vice president, giving a presentation developed by the syndicate for its members and looks forward to this stimulating greater action within the energy sector.

"Without access to clean, modern — particularly renewable — energy, all healthcare workers must carry out work in substandard conditions, which jeopardises provision of safe, effective, quality and affordable medicines and healthcare services. In addition, the use of fossil fuels contributes to air pollution and respiratory diseases. We are pleased to work with other sectors, united with FIP, towards achieving the Sustainable Development Goals and universal health care."

Dr Prosper Hagg
President, African Pharmaceutical Forum

Unifying organisations on non-communicable diseases

Non-communicable diseases (NCDs) are a major challenge to the health systems of all countries, regardless of their wealth or state of development. Quality care of NCDs is imperative to better primary health care (see p12). Under its Practice Transformation Programme on Non-Communicable Diseases FIP developed several handbooks, knowledge and skills reference guides and videos in 2022 (see p35) to help ensure that pharmacists are equipped to support people with NCDs, including through expanded pharmaceutical services, addressing all five major NCD areas: cardiovascular diseases, chronic respiratory diseases, cancer, diabetes, and mental health. Furthermore, FIP brought together international experts and collaborated with a number of organisations to develop some of these resources, including the European Society of Clinical Pharmacy, the International Primary Care Respiratory Group, the International Society of Oncology Pharmacy Practitioners and the World Heart Federation.

"Oncology is an area where change is at its most rapid and where pharmacists are well poised to significantly implement many of the new treatments, technologies and research in cancer care. This handbook [on cancer] and its accompanying knowledge and skills guide cover a lot of ground and provide a comprehensive foundation...I am excited for the impact that FIP’s Practice Transformation Programme on NCDs and accompanying resources will have on elevating the quality and consistency of oncology pharmacy practice globally."

Dr Evelyn Hande
President, International Society of Oncology Pharmacy Practitioners

"The World Heart Federation applauds the important and timely work undertaken by FIP to develop this handbook [on cardiovascular diseases]. We hope it is used widely. The challenge of CVD is sizeable, but in working together towards the goal of ensuring everyone has access to the information, care and treatment they need, we are taking important steps towards tackling it."

Prof Fausto Pratt
President, World Heart Federation

Accelerating workforce development

There are common practice advancement attributes that can be developed into competencies for all practitioners. FIP Education director Prof. Ian Bates told over 1,500 participants at an event organised by the Indonesian Pharmacists Association in March. The webinar, which focused on pharmacy workforce advancement and pharmacy career pathways in Indonesia, was attended by pharmacists and other healthcare professionals, as well as Ministry of Health personnel. It stimulated discussion on encouraging the issuance of regulations related to advanced pharmacy practice in Indonesia in synergy with the career development programme for pharmacists across practice sectors. Work to advance pharmacy practice also included the largest and most comprehensive global study to date on pharmacy advanced practice models around the world, conducted by the FIP Hub (see p26). The findings were published in BMJ Open in May as a paper entitled “Strengthening primary healthcare through accelerated advancement of the global pharmacy workforce: a cross-sectional survey of 88 countries”.

“The Indonesian Pharmacists Association has been working with FIP since 2019 through the workforce transformation programme. With support from FIP, we have developed the Indonesian Advanced Development Framework. We are now in the phase of implementing a career development programme by coordinating and collaborating with the Ministry of Health in Indonesia. We thank FIP for its support in our webinar, which showed what practice in other countries looks like. FIP has provided credible sources and materials for Indonesian pharmacists to advance pharmaceutical practice in the future.”

Prof. Keri Lestari Dandar
Vice President on Education and Advance Career Pharmacist, Indonesian Pharmacists Association

Tracking sector trends

Trends in the eight major pharmacy sectors were identified by FIP’s Board of Pharmaceutical Practice and shared in a report, "Trend analysis report amid the COVID-19 pandemic 2021-2022", published in October. The report presents directions identified by each of FIP’s sections, classing them into six major trend groupings, including expanding scope of practice and health security, economic and distribution concerns.

“FIP’s most valuable asset is its people: the network of pharmaceutical healthcare experts it brings together. Through their commitment and practice they combine knowledge and adaptability so our profession can navigate the challenges of the present and future, to better serve our communities and healthcare systems. The (trends) report, offering insight into each sector of pharmacy practice, can be used as a strategic tool in planning for the developments ahead that will impact on how we work as the world emerges from the COVID-19 pandemic.”

Dr Daragh Coughlin
Chair, FIP Board of Pharmaceutical Practice

Annual Report 2022 One FIP — United for a healthier world
Health benefits for patients and communities

Increasing availability of point-of-care tests

Pharmacy screening services greatly contribute to public health and the efficiency and sustainability of healthcare systems. They are an important stepping-stone towards universal health coverage. In September, the FIP Council adopted a new policy statement on health screening through pharmacy point-of-care testing as a means towards a healthier world. A broad range of point-of-care tests can be performed in pharmacies, from screening for diseases (e.g., HIV) to monitoring chronic disease indicators (e.g., testing for cholesterol). In the new statement, FIP calls for pharmacy testing services to be incorporated into publicly funded and insurance-funded health care as well as being available for purchase by individuals, and for pharmacists to have read-and-write access to electronic health records so that test results can be shared across the healthcare team. FIP policy statements are an advocacy tool that can be used to advance the pharmacy profession. (See p29 for other FIP Council decisions in 2022.)

“The World Health Organization has said that when point-of-care tests are adequately performed, they improve quality of care. With this [new] policy statement, FIP is leading on point-of-care testing in pharmacy settings as a way to strengthen health systems around the world. This is particularly important in low- and middle-income countries to ensure affordable access to health services. It is crucial for pharmacy professionals to be included in national and local strategies.”

Dr. Julien Fonsart
president, FIP Clinical Biology Section

Improving access to medicines through biowaivers

The biowaiver pathway represents an accelerated regulatory strategy for development of generic immediate-release solid oral dosage forms without the requirement for human in vivo bioequivalence studies. Selection criteria suitable for a biowaiver critically affect the timeline as well as costs associated with market approval of a generic product while simultaneously assuring the quality of the medicine. The Biopharmaceutical Classification System represents the scientifically accepted framework for many regulatory authorities to grant a waiver from mandatory bioequivalence studies. Due to high variability in literature data, the World Health Organization revised in 2016 its Guidance on Waiving of Bioequivalence Requirements for Immediate-release Oral Solid Dosage Forms to require experimentally determined laboratory data using a globally harmonised protocol. FIP’s Board of Pharmaceutical Sciences (BPS) and various academic institutional members have supported this initiative since 2017 and actively contributed to the experimental solubility assessment of qualified active pharmaceutical ingredient from the WHO Essential Medicines List. In 2022, the BPS led a One FIP project to develop a roadmap for the development of and access to biowaivers in Latin America. Through a series of digital events in Spanish and English that reached more than 1,200 attendees, FIP built collaborations with partners in South America to raise awareness of this science-based regulatory pathway as a way to improve access to safe and effective generic drugs. Around 50% of Latin American countries lack defined bioequivalence standards and the aim was to engage with regional health authorities and facilitate discussions about harmonisation of the biowaiver approval pathway, raise awareness among pharmaceutical companies regarding biopharmaceutics classification system concepts, and promote collaborations between universities to generate scientific evidence in support of biowaiver approval pathway and increase workforce capacity in the region. “This ongoing work on biowaivers, in collaboration with the WHO, is of huge importance to the One FIP agenda. The outcomes of this project will be shared through further digital events and we are preparing several manuscripts for publication in peer-reviewed journals. We want to take the regional approach in Latin America to other regions,” said Giovanni Pauletti, FIP scientific secretary.

“The Latin American Biowaiver project is an important resource to disseminate scientific and regulatory knowledge in the region. As a regulator, we were able to connect to other health authorities and understand how we could work together.”

Dr. Alexis Aceituno
head of the Subdepartmental Sanitary Registry of Bioequivalent Pharmaceutical Products, Public Health Institute of Chile

Boosting care for COPD patients

Chronic obstructive pulmonary disease (COPD) has a significant negative impact on quality of life, yet is under-prioritised, under-funded and undertreated compared with other non-communicable diseases. In November, FIP was part of a coalition of healthcare professions and the pharmaceutical industry calling on governments and healthcare system leaders to recognise COPD as a public health priority. The joint declaration called for investment in quality COPD services and national respiratory strategies (similar to national programmes for oncology and diabetes) to support public health interventions and health service transformation, while measuring progress against the Sustainable Development Goals. A recent Lancet Commission noted that factors such as air pollution are likely to overtake tobacco smoking as the leading cause of COPD. In 2022, FIP continued to raise awareness of pharmacists’ roles in reducing the health impact of pollution through two digital events:

“FIP’s endorsement of the Speak Up for COPD Joint Declaration demonstrates commitment by the pharmacy profession to work with patient advocates, clinicians and other stakeholders to address the burden of COPD on a global scale. The endorsement also provides a strong message to policymakers, highlighting the importance of COPD as a public health issue, and the need for sustained action and investment in research and treatment.”

Ms Tonya Winders
president and CEO, Global Allergy and Airways Patient Platform, and Speak Up for COPD coalition chair

Meeting the needs of children

Extemporaneous compounding of medicines for children is common practice in pharmacies in order to provide age-appropriate dosage forms. However, national and regional studies have shown considerable variability in current practices and regulations. In 2022, FIP’s Paediatric Formulations Focus Group conducted a global survey on the most frequently compounded oral paediatric medicines: 730 responses were collected and analysed. It confirmed not only a diversity in practices, but also a common global need for freely accessible compounding formulations, stability studies and information resources. The focus group is preparing to publish its findings. “The next steps are the global harmonisation of compounding practices and the identification of formulations that are robust, safe, stable, palatable and feasible, and making these publicly available, and to prepare our workforce so that they adopt best practices in oral compounding,” said Hala Fadda, chair, FIP Paediatric Formulations Focus Group.

“Meeting the needs of children, particularly in low- and middle-income countries, is preparing to publish its findings. The next steps are the global harmonisation of compounding practices and the identification of formulations that are robust, safe, stable, palatable and feasible, and making these publicly available, and to prepare our workforce so that they adopt best practices in oral compounding.”

Ms Tonya Winders
president and CEO, Global Allergy and Airways Patient Platform, and Speak Up for COPD coalition chair

Supporting health during the Ukraine emergency

FIP responds to direct requests from its members in line with its vision. In recent years, it has offered support of differing kinds to colleagues in Afghanistan, Ethiopia, Lebanon and Sudan. As war broke out in Ukraine in February, FIP responded to requests for support from the All-Ukrainian Pharmaceutical Chamber as follows:

• A humanitarian aid fund was set up for monetary donations;
• FIP’s Military and Emergency Pharmacy Section made medication instructions/pictograms available in Polish, Russian and Ukrainian;
• A statement as part of the World Health Professions Alliance, calling for an immediate end to war in Ukraine;
• Publication of equivalence tables for medicines registered in Ukraine to facilitate pharmaceutical care to refugees;
• Guidance to facilitate the integration of the refugee pharmacy workforce from Ukraine;
• Sharing International League Against Epilepsy resources relevant to pharmaceutical care of people with epilepsy and in crisis situations; and
• Sharing work undertaken by the Pharmacists’ Defence Association (UK), to coordinate medicines supplies and legal and ethical frameworks (all of which FIP will share in preparation for future crises).

“The All-Ukrainian Pharmaceutical Chamber with the full support of FIP and the Pharmaceutical Group of the European Union launched the largest in this century professional pharmaceutical charity movement to provide humanitarian assistance to Ukraine with medicines and medical devices, under the slogan ‘Pharmacists of the world for Peace on Earth’. We Ukrainians thank the world pharmaceutical community for its support.”

Oleksandr Romanda, Ukraine’s First Deputy Minister of Health, thanked FIP for its “valuable cooperation” and the pharmacy profession for its care of the health needs of the thousands who had to flee the country.

“Meeting the needs of children, particularly in low- and middle-income countries, is preparing to publish its findings. The next steps are the global harmonisation of compounding practices and the identification of formulations that are robust, safe, stable, palatable and feasible, and making these publicly available, and to prepare our workforce so that they adopt best practices in oral compounding.”

Dr. Alexis Aceituno
head of the Subdepartmental Sanitary Registry of Bioequivalent Pharmaceutical Products, Public Health Institute of Chile

Dr Julien Fonsart
president, FIP Clinical Biology Section

Ms Tonya Winders
president and CEO, Global Allergy and Airways Patient Platform, and Speak Up for COPD coalition chair

Oleksandr Romanda, Ukraine’s First Deputy Minister of Health, thanked FIP for its “valuable cooperation” and the pharmacy profession for its care of the health needs of the thousands who had to flee the country.

“The All-Ukrainian Pharmaceutical Chamber with the full support of FIP and the Pharmaceutical Group of the European Union launched the largest in this century professional pharmaceutical charity movement to provide humanitarian assistance to Ukraine with medicines and medical devices, under the slogan ‘Pharmacists of the world for Peace on Earth’. We Ukrainians thank the world pharmaceutical community for its support.”

Oleksandr Romanda, Ukraine’s First Deputy Minister of Health, thanked FIP for its “valuable cooperation” and the pharmacy profession for its care of the health needs of the thousands who had to flee the country.

“Meeting the needs of children, particularly in low- and middle-income countries, is preparing to publish its findings. The next steps are the global harmonisation of compounding practices and the identification of formulations that are robust, safe, stable, palatable and feasible, and making these publicly available, and to prepare our workforce so that they adopt best practices in oral compounding.”

Dr. Alexis Aceituno
head of the Subdepartmental Sanitary Registry of Bioequivalent Pharmaceutical Products, Public Health Institute of Chile

Dr Julien Fonsart
president, FIP Clinical Biology Section

Ms Tonya Winders
president and CEO, Global Allergy and Airways Patient Platform, and Speak Up for COPD coalition chair

Oleksandr Romanda, Ukraine’s First Deputy Minister of Health, thanked FIP for its “valuable cooperation” and the pharmacy profession for its care of the health needs of the thousands who had to flee the country.
Transforming education and workforce

Developing competency frameworks for the workforce

FIP provided technical input to a new Global Competency and Outcomes Framework for Universal Health Coverage published by the World Health Organization (WHO) in April 2022. The framework is addressed to member states and educational institutions to support them in identifying health worker education outcomes, integrating the framework within education programmes; establishing standards for practice; and building performance appraisal tools. “This landmark project directly addresses the need to enhance the generic competencies of the global healthcare workforce and clearly sets out competency-based education as the most effective approach for this. In alignment with other healthcare professions, the WHO UHC framework provides a blueprint for career-long pharmaceutical education and workforce development, ensuring that the needs of both patients and healthcare systems are a focus,” said FIP Education Director Ian Bates, who was a member of the framework’s working group. Work on competency-based education continued in 2022. In September, FIP defined competencies and behaviours for pharmacy educators and trainers in a global framework, along with a validated self-evaluation and career development tool. This was followed in November with the publication of a FIP handbook providing step-by-step guidance for educators to implement competency-based education concepts in their pharmacy education and training.

Addressing gaps in digital health education

FIP launched a “Train the trainer” online course on digital health in January, taking forward some of the recommendations in its 2021 report “Digital health in pharmacy education and workforce”. Developing a digitally enabled pharmaceutical workforce, which found that a large proportion of pharmacy schools and faculties did not offer digital health education or training and lacked experts and resources needed for digital health education. Over 230 people enrolled in the course, which consisted of three modules covering the integration of digital health in pharmacy education and digital health curriculum development, produced with the support of FIP’s Academic Pharmacy Section. An updated version of the course, taking participants’ feedback into account, is being prepared for 2023.

“[...] I was able to learn more about artificial intelligence ethics, mHealth, big data, application programming interfaces and many other relevant technologies to consolidate my knowledge in digital health, and how it can assist the development of the global pharmacy profession. I highly recommend all pharmacists enthusiastic about technology enrol in this essential [FIP] course for their digital health portfolio. The beauty of it is that you also join a forum with fellow students to share your insights and peer-review their work.”

Tackling inequities in education

A new resource to help academic institutions, policymakers, educators, faculty members and students address inequities in pharmaceutical education was launched by FIP in September. The “FIP tool kit for addressing inequities in pharmaceutical education” contains articles, interviews and country case studies from across the six World Health Organization regions that present these inequities as related to gender, race, ethnicity, religion, resources and education (e.g., access to schooling) and how they have been successfully addressed.

“UNESCO’s 2021 Global Education Meeting Paris declaration: A global call for investing in the futures of education” which is supported by FIP, emphasised the need to tackle the educational crises and inequalities exacerbated by the COVID-19 pandemic. Recent findings by FIP indicated that inequities exist in pharmaceutical education and these need to be addressed urgently. This new toolkit aims to motivate forward-thinking changes targeted at transforming pharmaceutical education through addressing inequities.

Taking forward training on falsified medicines

A comprehensive course on substandard and falsified (SF) medical products for pharmacy students, developed by FIP, the World Health Organization (WHO) and partners was piloted in five African universities and the findings were shared at a WHO-hosted roundtable in March. This work followed the development of a curriculum guide by FIP and the WHO in 2021 to improve action on SF medicines. The course formalises and structures information available to pharmacists, covering the root causes of SF medical products, early warning signals, good procurement practices, working with authorities, advice to patients, and more. At the roundtable, project managers, university professors and students involved in the pilots shared their insights.

“We were delighted to be selected to participate in the university SF curriculum pilot led by FIP in collaboration with WHO. Both lecturers and students found the modules so relevant to address practical detection, prevention and response knowledge and skills gap. We have received three handheld near infrared pill scanners and this is going to revolutionise practical delivery of the modules. The pilot at our university coincided with a university-wide curriculum revision and upon implementation students were super excited the module formulated to address all practical issues. We thank FIP and WHO.”

Developing policies for quality education

October saw two updated FIP Statements of Policy in the area of education. The first, on continuing professional development (CPD), makes clear that pharmacists acquiring, developing and maintaining professional competence throughout their careers is a fundamental and ethical requirement, and sets out FIP’s commitments to help them achieve this. Whereas a statement in 2002 defined CPD and continuing education, and made general recommendations, the updated statement contains a number of recommenda- tions specifically for government agencies and policy-makers, national pharmaceutical associations, CPD providers, employers and for pharmacists themselves. The second new policy statement describes standards for assuring the quality of pharmacy and pharmaceutical sciences education.

“As additional roles for pharmacists are increasingly recognised, many countries have undertaken a major transformation of pharmacy and pharmaceutical sciences education. However, not all countries have a national system for quality assurance (QA) of education, leaving adherence to international or regional QA standards as an option for higher education institutions, and this leads to heterogeneity in workforce competencies. Quality assurance is important for maintaining the quality of education in order to support the development of an adequate and appropriate pharmaceutical workforce.”
Collaborations and partnerships

Improving access to vaccines

Work to increase immunisation through pharmacies included the publication of several new resources in 2022 (see p33). In addition, vaccination is an area in which FIP collaborates with a variety of organisations towards a common goal of better access. In March, FIP CEO Catherine Duggan was a panellist at the launch of the International Longevity Centre UK report “Generation X: Leveraging intergenerational relations to increase uptake of vaccination.”

In October at an Immunisation For All Ages coalition event at the World Health Summit in Berlin, Germany, Gonçalo Sousa Pinto, FIP lead for practice development and transformation, highlighted how an increased number of countries in which pharmacists have gained the authority to administer vaccines has expanded immunisation coverage and reduced morbidity and mortality. The year also saw a series of FIP roundtables bringing together national pharmacy organisations, universities, regional pharmaceutical forums, ministries of health, national vaccine advisory committees, regulators, centres for disease control and surveillance and civil society. The events, led by the FIP Regulators Advisory Group, enabled a discussion of the challenges and enablers to leveraging pharmacists as vaccinators.

FIP published the outcomes from these discussions in July, serving as a starting point for more vaccine-related discussions around the world in order to enable multiprofessional vaccine prescribing and administration as a patient-centred approach. FIP is proud that 20 stakeholders voiced their confidence in the value of pharmacists and FIP in advancing the widespread utilisation of pharmacists to build vaccine confidence through their public endorsement of FIP’s commitment on this issue made in April. These organisations included the Active Citizenship Network, the European Interdisciplinary Council on Ageing, Immunize.org, the Influenza Diabetes Community/European Scientific Working Interdisciplinary Council on Ageing, the European Federation of Public Health Associations.

Supporting self-care

FIP’s ongoing partnership with the Global Self-Care Federation (GSCF) to increase self-care continued in 2022. FIP supported the GSCF proposal for a World Health Organization Resolution on self-care in order to encourage guidelines and create a global policy pipeline. FIP CEO Catherine Duggan represented pharmacy’s perspectives on current policies on self-care at a GSCF event in March. The role pharmacists have in supporting greater integration of self-care in health systems was presented by FIP in 2022 to educate pharmacists not only about different types of vaccines but on population priorities and the preparations required to provide influenza immunisation services in pharmacies.

In addition, the Australian Pharmacy Council was the first accreditation agency to be awarded the FIP Seal. “We have been pleased to work with in partnership with FIP in 2022 to educate pharmacists not only about different types of vaccines but on population priorities and the preparations required to provide influenza immunisation services in pharmacies. FIP’s goals and values have helped us reach many pharmacists with a flexible medical education option that allows them to educate themselves from anywhere at any time.”

Promoting positive practice environments

FIP is proud to be a founding member of the World Health Professions Alliance (WHPA), which speaks for over 45 million health professionals worldwide. In 2022, the alliance focused its efforts on two main areas — its “Stand up for positive practice environments” campaign and international relations and visibility, especially related to the impact of COVID-19 on health professionals globally. FIP represented the alliance at the 250th session of the World Health Organization (WHO) Executive Board in January, calling for countries to urgently increase investment in health systems and address safety risks to health workers. In unity, the alliance of pharmacists, physicians, nurses, dentists and physical therapists drew attention to a deterioration of working conditions, professional shortages and service disruptions that have severely impacted on people’s health and said that governments must work with health professions on ways forward. The WHPA also called on governments to work more closely with health professions on implementing the 2023-2030 roadmap for the global action plan for the prevention and control of non-communicable diseases. And it asked for World Health Assembly side events to be kept because they are useful platforms for non-state actors to engage and collaborate with member states and WHO, allowing exchange of expertise on technical matters. November saw collaboration on priority health workforce issues as well as universal health coverage, non-communicable diseases and ageing populations cemented between members of the alliance and the WHO with the signing of a memorandum of understanding in Geneva, Switzerland. This signing reflects an integrated multi-stakeholder approach, providing a framework for joint action and contributing to reinforcing national and regional health systems and services.

“That with this MoU, WHPA and WHO will support healthcare professional associations and associations to protect and invest in the multidisciplinary teams of health workers needed to deliver essential health services and prevent and respond to emergencies.”

More collaborations

FIP also recognises collaborations with the following organisations:

- Commonwealth Pharmacists Association
- Economist Intelligence
- European Society of Clinical Pharmacy
- International Diabetes Federation
- International Committee of Military Medicine
- International Alliance of Patient’s Organizations
- International Federation of Pharmaceutical Manufacturers’ Associations
- International Primary Care Respiratory Group
- International Society of Oncology Pharmacy Practitioners
- Pfizer Foundation (an independent research arm of Pfizer)

- “Role of pharmacists in allergic rhinitis” (Omninicus Healthcare Pvt Ltd in collaboration with Medical Affairs, Viatris); and
- “Vaccine and injectable medicines administration” (National Association of Pharmacies, Portugal).

In addition, the Australian Pharmacy Council was the first accreditation agency to be awarded the FIP Seal. “We have been pleased to work with in partnership with FIP in 2022 to educate pharmacists not only about different types of vaccines but on population priorities and the preparations required to provide influenza immunisation services in pharmacies. FIP’s goals and values have helped us reach many pharmacists with a flexible medical education option that allows them to educate themselves from anywhere at any time.”

Ms Savitha Kuttan
CEO, Omnicurs
World Pharmacists Day

FIP WORLD PHARMACISTS DAY 2022
25 September

The theme of FIP’s 12th World Pharmacists Day campaign, which also marked FIP’s 110th birthday, was “Pharmacy united in action for a healthier world.” We know that WPD was marked in at least 140 countries. The value of pharmacy was talked about in national newspapers and on the radio. WPD2022 messages from health ministers and health systems recognised our profession’s contribution to health care. Pharmaceutical companies, wholesalers, other corporates in the health sector and even financial institutions also took the opportunity to thank pharmacists for their efforts to make medicines expertise and healthcare accessible to all. In particular, FIP member organisations participated in a multitude of ways, from holding events to measure blood pressure and promote healthy exercise to holding press conferences and running competitions to advocate for the profession. Details of such activities can be found here. In addition, over 3,000 colleagues from different sectors took part as FIP WPD2022 Champions, sharing the message through their networks.

FIP’s 2022 campaign successfully showed how our profession is united, regardless of and overcoming conflict, different politics and cultures, and economic disparity, and how each and every day the pharmaceutical profession is acting to achieve good health and well-being for all.

The Canadian Pharmacists Association shared the finding of a new survey that 90% of Canadians think pharmacists can help address gaps in care caused by the shortage of health providers.

Indonesian Pharmacists Association events featured on national television.

The Bulgarian Pharmaceutical Union raised awareness on prescription bags and achieved front page coverage in the national newspaper 24 Chasa.

The Canadian Pharmacists Association shared the finding of a new survey that 90% of Canadians think pharmacists can help address gaps in care caused by the shortage of health providers.

The Ordre National des Pharmacien de Madagascar raised awareness of pharmacy among young people.

The Malaysian Pharmacists Society Young Pharmacists Chapter launched a video competition called “My Little Pharmacist”, to educate children on the role of the pharmacist.

World Pharmacy Week 2022
In 2022, FIP held its third World Pharmacy Week from 19 to 25 September, and there was no better time and place for this to take place than during the FIP world congress in Seville, Spain (see p25). In addition to gathering pharmacy professionals from at least 100 countries, the week saw:

• The launch of a global competency framework for the pharmaceutical education sector by FIP to support advancement through personal and professional development;
• Advocacy by the FIP president in the Parliament of Andalusia, Spain, for pharmacy’s role in universal health coverage;
• A new FIP Policy Statement on health screening through pharmacy point-of-care tests;
• A FIP commitment to six actions to support the pharmacy profession through disasters; and
• Publication of FIP’s global roadmap to support pharmacy transformation to 2030.
"Pharmacy united in the recovery of health care" was the theme of FIP’s 80th World Congress of Pharmacy and Pharmaceutical Sciences, which was held in Seville, Spain, from 18 to 22 September, and co-hosted by the General Pharmaceutical Council of Spain.

There were 2,275 participants, from 101 countries, including 70 speakers. There were 25 sessions (three plenary and 22 in parallel), and a total of 615 posters were presented.

Spain’s national health minister Carolina Darias and Catalina Garcia Carrasco, councillor for health and consumer affairs for the region of Andalusia, addressed congress delegates at the opening ceremony, both recognising the role that pharmacy plays in reinforcing health systems.

The global health emergency of COVID-19 has proved that pharmacists and pharmacies are “integral to a well-functioning healthcare system” and that the profession has advanced at an “unprecedented rate”, expanding its scope of activities to provide more services, FIP president Dominique Jordan said in his presidential address at the opening ceremony.

The congress programme covered broad topics such as learnings for future preparedness, science and evidence supporting the response to COVID-19, and dealing with new and extraordinary ethical challenges. In addition, sessions on digital health, antimicrobial resistance, vaccine technology and drug delivery were on offer, as well as an Early Career Pharmaceutical Group Leadership Development Workshop.

"Seville has given us the opportunity to continue showing the world the greatness of the pharmaceutical profession. Pharmacy has shown that is knows how to be proactive and generate solutions to tackle the pandemic and guarantee access to medicines for patients."

Mr Jesus Aguilar Santamaria
president, General Pharmaceutical Council of Spain

"I was honoured to be invited to present the EPhEU project Medicines to Ukraine at the FIP congress. It gave us the opportunity to show what pharmacists can do. It was important for colleagues around the world to hear how the project was organised and how only pharmacists had the knowledge and expertise to provide safe, transparent and efficacious delivery of needed medicines. FIP is the global organisation that gathers all pharmacists, so we are proud that FIP recognised this EPhEU project as important for all pharmacists."

Dr Katarina Fehir Šola
president, European Association of Employed Community Pharmacists (EPhEU) (Austria)

"It was a great pleasure to reunite with many friends and colleagues around the world at the FIP congress in Seville, and to make new acquaintances. The congress provided opportunities to learn about the latest developments in pharmacy and find out about new data. It also felt good to be able to share experiences from my country. The FIP congress removes country and areas of practice borders, allowing us, the whole profession, to share and work together for the betterment of health."

Mr Chang Seok Goo
congress participant (South Korea)

"Pharmacy is vital in strengthening our health systems. Experiences related to advancing roles must be shared so that countries can learn from each other," said FIP president Dominique Jordan at a press conference.

Mr Jesus Aguilar Santamaria
president, General Pharmaceutical Council of Spain

Over 600 posters were presented.

The FIP AIM Global Academic Leaders Forum World Café facilitated small group roundtable discussions around topics of critical importance to academic leaders.

People met face to face after three years.
Awards*

Recognising achievements in health promotion and pharmacy practice

In 2022, FIP renewed its range of awards following review by an FIP Awards Committee in 2020 and continued work in 2021 by a new FIP Awards Working Group. The changes aimed to enhance the unique value of FIP awards, reduce competition with other organisations and increase benefit to FIP and its members. Other objectives of the review were to explore how non-members could be recognised, to recognise early and mid-career colleagues for service, and to reward excellence in education and workforce development as well as in science and practice. The first year in a new three-year FIP awards cycle recognised 32 pharmacy professionals from nine countries.

The André Bédat Award, FIP’s highest honour for pharmacy practitioners, was given to Dr Roberto Frontini (Germany).

The FIP Distinguished Pharmaceutical Science Award (mid-career) went to Prof. Yahya Choonara (South Africa).

Dr Betty Lentani (Australia) received the FIP Pharmaceutical Education Recognition Award (early career).

FIP’s Academic Pharmacy Section awarded two grants for projects to:

- Dr Mohamed H. El-Naem (Malaysia) for “Telepharmacy practice module for students: Training and upskilling of Malaysian future pharmacists to provide sustainable remote pharmaceutical care services”, and
- Dr Annola Joda (Nigeria) for “The psychological impact of COVID-19 on the mental health of staff and students in the faculties of pharmacy and education in two universities in Nigeria”.

FIP’s Health and Medicines Information Section awards

FIP’s Health and Medicines Information Section (HAMIS) made awards as follows:

- Ms Fernanda Lacerda da Silva Machado (Brazil) received the HAMIS 2020 Stipend (transferred to 2022 because of the COVID-19 pandemic);
- Ms Marilta Putri Ekasari (Indonesia/UK) received the HAMIS 2022 Stipend; and
- Ms Rendani Tshilambwana (South Africa) received the HAMIS FIP Congress Poster Award for her work “Medication refill adherence amongst patients in the Central Chronic Medicines Dispensing and Distribution Programme in two districts of KwaZulu-Natal, South Africa, prior to and during the COVID-19 pandemic”.

Hospital Pharmacy Section awards

Three research grants were awarded by FIP’s Hospital Pharmacy section (HPS) to:

- Ms Martina Francis, The University of Sydney, Australia, Dr Laurel Legenza, University of Wisconsin-Madison, United States, and Ms Tilaylo Ondu, Association of Hospital and Administrative Pharmacists of Nigeria.

FIP’s HPS Congress Poster Award went to Ms Christine Choo (Singapore) for her work “Streamlining pharmacy discharge processes for COVID-19 patients in a paediatric hospital”.

Social and Administrative Pharmacy Section awards

FIP’s Social and Administrative Pharmacy Section (SAPS) gave the following awards for FIP congress posters:

- Dr Jack Collins (Australia) and Dr Suzete Costa (Portugal) were named joint first place for “Patient preferences and cost benefit of hypertension and hyperlipidaemia collaborative management model between pharmacies and primary care in Portugal: a discrete choice experiment alongside a trial” and “Implementing a cluster-RCT of a community pharmacist-led intervention to support consumers living with severe and persistent mental illness: Bridging the gap between physical and mental illness”, respectively.
- Ms Sonia Romano (Portugal) received an award for “The impact of community pharmacies on regional equity in access to professional rapid antigen testing for SARS-CoV-2 in Portugal”.

Mr Sylvester Adeyemi was given the SAPS Research Award for a project “Community pharmacist-administered COVID-19 vaccinations in Abuja, Nigeria: A patient survey on satisfaction and motivation to get vaccinated”.

The Health Promotion Campaign Award for a FIP member organisation and the Pharmaceutical Science Organisational Award were not given.
Elections and Council decisions

The FIP Council, through which all member organisations have voting rights, meets at least once a year. In 2022, two extraordinary meetings were held in April and December. Decisions made at these meetings included the following.

FIP Statutes
The Council adopted a Rule of Procedure whereby member organisations can suggest amendments to the FIP Statutes which can be reviewed and considered every three years.

Integration of the regional pharmaceutical forums
The Council voted in favour of a proposal to integrate three regional pharmaceutical forums that were ready for full integration — African Pharmaceutical Forum, Eastern Mediterranean Pharmaceutical Forum, and South East Asian Pharmaceutical Forum — and, pending successful negotiations, the Pharmaceutical Forum of the Americas and the Western Pacific Pharmaceutical Forum. The proposal included next steps such as drafting common statutes and use of the FIP logo alongside the forum logo.

Elections and ratifications
The Council elected the next president of FIP.

Policies
The FIP Council adopted Statements of Policy on:
- The role of pharmacy in point of care testing
- Continuing professional development
- Quality assurance of pharmacy and pharmaceutical sciences education

Three new vice presidents were elected:
- Dr Prosper Hia (Cameroon)
- Dr Marianne Ivey (USA)
- Dr Virginia Olmos (Uruguay)

The Council ratified:
- Dr Carlos Lacava (Uruguay) as the new chair of the Board of Pharmaceutical Practice

In 2022, three FIP Bureau members ended their terms of service. We acknowledge their work and dedication to our federation, and asked them for their views on being united for a healthier world.

“Four years I had the honour of serving as vice president of FIP. It was an absolutely incredible experience, which began at the Glasgow congress in 2018 and culminated in the reunion that was the Seville congress 2022. I am deeply grateful to the AFGU [the Uruguay Association of Chemistry and Pharmacy] for supporting my running for office and to all the FIP member organisations that voted for me. This period was one of transformation, coinciding with the beginning of Dominique Jordan’s presidency and a new vision of FIP. It was also the start of the CEO Catherine Duggan, who has demonstrated capability in this role. But, above all, we faced a pandemic. FIP not only kept up its activities but increased them to support the profession. Lots of webinars kept pharmacists up to date with information about COVID-19 and the FIP Bureau frequently met virtually. Throughout the pandemic, our profession, through its actions, has proven its great value. I am proud to continue to belong to an organisation that unites the profession for a healthier world.”

Ms Samira Shammas Goussous (Jordan) vice president, 2018–22

“It’s been both a privilege and a pleasure to serve as vice president. In these four years, we’ve seen our profession of pharmacists around the world come together to support other members of the pharmacy team, the wider healthcare team, health systems and, ultimately, the public. This solidarity was catalysed by the COVID-19 pandemic, but FIP has been a key enabler. Our federation has shown, be it through new digital events or through the FIP world congress, that, more than ever, collaboration and sharing across borders is key to finding new solutions to the challenges our health systems face. It has been exciting to see how the regional forums have become closer to the heart of FIP supported through my colleagues on Bureau and the executive, led by Dominique Jordan as president and Catherine Duggan as CEO. Being the Bureau lead for the South East Asian Region Pharmaceutical Forum gave me a great insight into the challenges and opportunities across that region. I was also incredibly proud of being part of the creation and development of the FIP Consortium and would like to pay particular tribute to Bronwyn Clark as chair and Dalia Bajis as executive lead, as well as to the new generation of pharmacy professionals. All the planned activities, programmes, statements and educational resources will promote the federation as One FIP. I am excited by the opportunities to contribute as an officer and proud of being a pharmacist and a member of FIP.”

Dr Virginia Olmos (Uruguay) vice president, 2018–22

“My journey with FIP started when I attended my first conference in Cannes, in 1998. My attendance was not on regular basis until early 2000 when I was asked by the then president Peter Kielgast to join a working group headed by Henri Manasse to redefine FIP membership. In 2002, I represented my country at the founding of the Eastern Mediterranean Pharmaceutical Forum before being elected a FIP vice president. In 2009, FIP along with the Jordan Pharmacists Association convened the first regional conference in Amman. This wealth of experience enriched my belonging to the profession and widened the circle of my social network within the profession globally. I have witnessed how FIP has become the hub for the scientist, the educator and the practitioner, bridging relations with global health institutions, empowering the pharmacist as a healthcare provider, aligned with the global agenda. FIP is moving closer to the regions and its member organisations as well as to the new generation of pharmacy professionals. All the planned activities, programmes, and initiatives will promote the federation as One FIP. I am blessed to have had the opportunity to contribute as an officer and proud of being a pharmacist and a member of FIP.”

Dr Marianne Ivey (USA) vice president, 2018–22

“My journey with FIP started when I attended my first conference in Cannes, in 1998. My attendance was not on regular basis until early 2000 when I was asked by the then president Peter Kielgast to join a working group headed by Henri Manasse to redefine FIP membership. In 2002, I represented my country at the founding of the Eastern Mediterranean Pharmaceutical Forum before being elected a FIP vice president. In 2009, FIP along with the Jordan Pharmacists Association convened the first regional conference in Amman. This wealth of experience enriched my belonging to the profession and widened the circle of my social network within the profession globally. I have witnessed how FIP has become the hub for the scientist, the educator and the practitioner, bridging relations with global health institutions, empowering the pharmacist as a healthcare provider, aligned with the global agenda. FIP is moving closer to the regions and its member organisations as well as to the new generation of pharmacy professionals. All the planned activities, programmes, and initiatives will promote the federation as One FIP. I am blessed to have had the opportunity to contribute as an officer and proud of being a pharmacist and a member of FIP.”

Prof. Ashok Soni (UK) vice president, 2018–22

Mr Carlos Lacava (Uruguay) vice president, 2018–22

Mr Paul Sinclair (Australia) will take office in September 2023.
FIP Digital Events

In 2022, over 21,000 people from over 170 countries and territories attended FIP’s Digital Events. A total of 115 digital events were developed and delivered, including series on:

- Advancing pharmaceutical care across Africa;
- Air pollution;
- Antimicrobial stewardship (in collaboration with the Commonwealth Pharmacists Association);
- Biowaivers in Latin America;
- Digital health;
- Evidence and impact, including creating FIP Development Goal indicators across the regions;
- Gut wellness;
- Healthy nutrition;
- How COVID-19 has changed pharmacy;
- Precision medicine; and
- Transforming pharmacy practice for improved care of non-communicable diseases.

FIP’s 10th FIP Global Pharmacy Technicians’ Symposium was held online in October. Resilience, global projects for pharmacy technicians, new roles for technicians, and sustainability in the health workforce were topics of discussion.

“The [technicians symposium] presentations provided a diverse range of perspectives with a unique opportunity to learn from experts and hear about cutting-edge research from up-and-coming professionals. The virtual environment also allowed for a wider range of attendees to participate, including those who might not have been able to attend in-person.”

Mr Cristiano Matos
vice president, European Association of Pharmacy Technicians

The wide range of digital event topics, many conceived and developed thanks to collaboration between a number of FIP constituents, demonstrate the many aspects of pharmacy that contribute to a healthier world. One example is the webinar “Combatting malaria: New horizon of vaccines and drug discovery by young pharmaceutical scientists”, organised by the Special Interest Group on New Medicines and the New Generation of Pharmaceutical Scientists Special Interest Group.

“We continue to be delighted with the good international attendance of FIP Digital Events. We monitor attendance and feedback to keep improving the experience of our participants,” said FIP chief operating officer and congress director, Carola van der Hoeff.

Recordings of FIP webinars are available at: https://events.fip.org/previous-fip-digital-events/

Precision medicine

Improved ability to predict which treatments will work best for specific patients is one of the advantages of precision medicine. 2022 saw the start of a new webinar series in this area. Organised by the FIP Technology Advisory Group and the Board of Pharmaceutical Sciences (Personalised and Precision Medicine Special Interest Group), these digital events discussed the current state and future of precision medicine in research and practice, including ongoing technological advances, and challenges and opportunities for the pharmacy profession to address.

“One FIP, as the FIP Technology Advisory Group & BPS Precision Medicine series (with particular support from Donnacha Fitzgerald of the FIP Technology Advisory Group) shows, is the right strategy to unleash the full utilisation of pharmacists’ expertise for the benefit of people and healthcare systems, and to support the science-based development of medicines and health technologies to meet healthcare needs. FIP advocates science and technology to build, together, a better pharmacy practice for the patients of today and tomorrow.”

Mr Jaime Acosta-Gomez
co-chair, FIP Technology Advisory Group

Pandemic preparedness

In the third year of the COVID-19 pandemic, part of FIP’s pandemic preparedness work included the series of digital events “How COVID-19 has changed us”, which covered both practice and science perspectives. Among the topics were managing workforce demand in a pandemic, delivering patient-centred support, and innovating in science to fight COVID and future pandemics.

“The pandemic cost too much in human lives and health, but it gave pharmacists the opportunity to be seen caring for their patients in new ways: in testing, vaccinating and treating. The FIP digital event facilitated the sharing of important information.”

Dr John Grabenstein
president, Vaccine Dynamics
Publications in 2022

FIP Development Goals report 2021
A global status update on the goals since their launch in 2020, a summary of programmes of work delivered in 2021, and global, regional and national needs and priorities related to transforming pharmacy.


Medication review and medicines use review: A toolkit for pharmacists
Update to the 2020 FIP medicines use review toolkit to reflect pharmacists’ wider medication review roles.

Shaping the future of self-care through pharmacy — I: Towards sustainable and universal healthcare systems and coverage and II: Self-care support for community pharmacy teams
Summaries of digital events series on policy and practice elements of pharmacists’ interventions in promoting informed self-care.

Guideline for establishing an early career pharmaceutical organisation
Key considerations for setting up an early career pharmaceutical organisation.

Empowering self-care. A handbook for pharmacists
Guidance on coaching practices and person-centred approaches to promoting and engaging in self-care.

Advocating expansion of the pharmacist’s role in immunisation: A focus on diphtheria-tetanus-pertussis booster, COVID-19 and meningitis vaccinations
Intelligence from 36 countries on pharmacists’ current role in vaccination services.

Guidance to facilitate the integration of the refugee pharmacy workforce from Ukraine
Based on information from the All-Ukrainian Pharmaceutical Chamber and developed with input from the FIP Regulators Advisory Group and FIP’s Workforce Development Hub.

Empowering self-care. A handbook for pharmacists
Guidance on coaching practices and person-centred approaches to promoting and engaging in self-care.

The FIP vaccination reference guide
Knowledge and skills to support professional development and inform pharmacy education in vaccination
Knowledge and skills that should be acquired by pharmacy students and obtained by pharmacists through professional development and training.

Transforming vaccination collection
Outcomes of FIP’s 2021 programme “Transforming vaccination globally, regionally, nationally: Accelerating equity, access and sustainability through policy development and implementation”.

The role of pharmacists in iron deficiency anaemia
Report of an advisory roundtable as part of FIP’s Multinational Needs Assessment Programme.

Regional challenges and enablers to leveraging pharmacists as vaccinators
Outcomes from a series of regional roundtables.

Mental healthcare — A handbook for pharmacists
Developed in collaboration with an international group of experts, presents the many potential mental health care actions that pharmacists can perform.

Knowledge and skills reference guide for professional development in mental health care
Intended to accompany the mental healthcare handbook.

Knowledge and skills reference guide for professional development in diabetes
Intended to accompany FIP’s diabetes handbook.

FIP handbook for providers of programmes
Supporting the FIP platform for provision through partnerships Provides guidance and context for potential providers of programmes about the FIP Provision and Partnerships Programme.

FIP handbook for accreditation agencies
Supporting the FIP platform for provision through partnerships Provides guidance and context for potential accrediting agencies about the FIP Provision and Partnerships Programme.

FIP engagement with our membership 2021
Capturing the voice of FIP members globally, to advance pharmacy worldwide (Member-only version & public version). An overview of the exchanges, national, and regional perspectives, and shared priorities and achievements at member engagement events.

Shaping the future of self-care through pharmacy — I: Towards sustainable and universal healthcare systems and coverage and II: Self-care support for community pharmacy teams
Summaries of digital events series on policy and practice elements of pharmacists’ interventions in promoting informed self-care.

Equivalence between medicines registered in Ukraine and other countries
Information for healthcare professionals and patients to facilitate pharmaceutical care to refugees from Ukraine.

Publications in 2022

Guideline for establishing an early career pharmaceutical organisation
Key considerations for setting up an early career pharmaceutical organisation.

Advocating expansion of the pharmacist’s role in immunisation: A focus on diphtheria-tetanus-pertussis booster, COVID-19 and meningitis vaccinations
Intelligence from 36 countries on pharmacists’ current role in vaccination services.

Guidance to facilitate the integration of the refugee pharmacy workforce from Ukraine
Based on information from the All-Ukrainian Pharmaceutical Chamber and developed with input from the FIP Regulators Advisory Group and FIP’s Workforce Development Hub.

The FIP vaccination reference guide
Knowledge and skills to support professional development and inform pharmacy education in vaccination
Knowledge and skills that should be acquired by pharmacy students and obtained by pharmacists through professional development and training.

Transforming vaccination collection
Outcomes of FIP’s 2021 programme “Transforming vaccination globally, regionally, nationally: Accelerating equity, access and sustainability through policy development and implementation”.

The role of pharmacists in iron deficiency anaemia
Report of an advisory roundtable as part of FIP’s Multinational Needs Assessment Programme.

Regional challenges and enablers to leveraging pharmacists as vaccinators
Outcomes from a series of regional roundtables.

Mental healthcare — A handbook for pharmacists
Developed in collaboration with an international group of experts, presents the many potential mental health care actions that pharmacists can perform.

Knowledge and skills reference guide for professional development in mental health care
Intended to accompany the mental healthcare handbook.

Knowledge and skills reference guide for professional development in diabetes
Intended to accompany FIP’s diabetes handbook.
Optimising vaccination through coadministration of influenza and COVID-19 vaccines

Guidance for pharmacists.

FIP toolkit for addressing inequities in pharmaceutical education

Articles, interviews and case studies from across the six World Health Organization regions that present inequities related to gender, race, ethnicity, religion, resources and education, and how they have been successfully addressed.

FIP global competency framework for educators & trainers in pharmacy

Developed by FIP’s Academic Pharmacy Section.

Cardiovascular diseases: A handbook for pharmacists

Developed in collaboration with the World Heart Federation and the European Society of Clinical Pharmacy.

Knowledge and skills reference guide for professional development in cardiovascular diseases intended to accompany the cardiovascular diseases handbook.

Sore throat: Quick reference guide for pharmacists

Guidance for community pharmacists.

Competency-based education in pharmacy and pharmaceutical sciences

Step-by-step guidance for educators to implement CBE concepts.

Sports pharmacy practice and education

Overview of how pharmacists have been using their knowledge and skills to act as key athlete support personnel through pharmaceutical care, doping control and providing services at sporting events.

Management of non-communicable diseases: Regulatory self-assessment and development tool for transforming pharmacy practice

Developed under the auspices of the FIP Regulators Advisory Group and based on experiences of the successful introduction of pharmacy services targeting NCDs and pharmacy practice legislation from around the world.

Vaccination of special-risk groups: A toolkit for pharmacists

Identifies six groups particularly susceptible to vaccine-preventable diseases and who could greatly benefit from support from pharmacists.

FIP Global Roadmap 2030: Sustainable advancement for pharmacy worldwide

High-level report by the FIP Bureau.

The global response of pharmacy to the pandemic: The contribution of the profession to COVID-19

Documents actions taken by FIP and presents findings of a sample of FIP member organisations on their pandemic activities, with information from 42 countries and territories.

FIP Education Transformation Toolkit

Support for pharmacy professional associations, universities and educators in advancing pharmaceutical education from undergraduate to continuing professional development.

FIP Statements of Policy

• The role of pharmacy professionals in point-of-care testing
• Continuing professional development
• Quality assurance of pharmacy and pharmaceutical sciences education

FIP commitments in 2022

• Leveraging pharmacists to build vaccine confidence and address vaccine hesitancy and complacency
• Humanitarian support in crises and disasters
• Antimicrobial resistance and antimicrobial stewardship by 2030
During 2022, FIP’s activities also included:

**Academic Institutional Membership (AIM)**
- The AIM leadership worked on a handbook containing examples of activities undertaken by AIM institutions to improve enrolment. The handbook was launched in January 2023. Access is an AIM benefit.

**Antimicrobial resistance**
- FIP conducted a survey of the content of pharmacy curricula in the context of antimicrobial resistance in order to address education and training needs. A report of the findings will be published in 2023.

**Communicable diseases and vaccination**
- FIP continued developing its series “Vaccines and special-risk groups” with new events and videos focusing on the vaccination of pregnant individuals and healthcare professionals released in quarter 1 of 2023. FIP is also developing a new policy statement on the role of pharmacists in life-course vaccination.

**Equity**
- An insight board gave country-level insights and shared best practices on the topic of pain and gender. A report of the meeting was released in January 2023. Work commenced on a new reference paper on access to medicines.

**FIP Compendium**
- In order to prepare evidence of impact of pharmacy and the contribution to Universal Health Coverage, as committed to in Astana in 2018, FIP began a process to compile a digest of a decade’s worth of publications and findings along with other literature related to the federation, since the FIP Centenary in 2012. The aim is to produce codified summaries identifying the cumulative impact of trends, descriptions of workforce and education developments, evidence of practice, workforce and policy transformation to be presented at FIP’s Health Ministers Summit in 2023. This will be continued on an annual basis to provide easy-to-access evidence of impact for advocacy and national support for initiatives.

**FIP congress**
- FIP’s 81st World Congress of Pharmacy and Pharmaceutical Sciences will be held in Brisbane, Australia, 24–28 September 2023.

**FIP Global Pharmaceutical Observatory**
- Under the Multinational Needs Assessment Programme, the GPO team conducted a study of what community pharmacy teams need to support good hygiene as part of people’s self-care and a report was published in February 2023. In addition, a FIP Development Goal indicator framework was developed to support tracking progress of the pharmacy practice, workforce/education and science elements of the DGs at national or member organisation level. Member organisations will be invited to test and use the framework.

**FIP Insight Board and roundtable reports**
- Self-care: Reclassification of medicines and its impact on access
- The role of pharmacists in managing reflux-like symptoms
- The role of pharmacists in promoting female intimate wellness

**Transforming conversations podcasts**
- Three in-depth conversations focusing on cases where pharmacists have brought about profound social, cultural and health change.

**Biowaiver monographs**
- For levamisole hydrochloride and levocetirizine dihydrochloride, developed by the Regulatory Sciences and Quality Special Interest Group’s Bioclassification/Biowaiver Focus Group.

**Translations**
- FIP Development Goals Handbook In Portuguese (thanks to the Association of Pharmacists of Portuguese-Speaking Countries) and Serbian (thanks to the Pharmaceutical Chamber of Serbia and the University of Belgrade Faculty of Pharmacy)
- FIP policy statement on the role of pharmacy professionals in point-of-care testing in Greek (thanks to the Federation of Pharmacists Cooperatives of Greece)

- Building vaccine confidence and communicating vaccine value: A toolkit for pharmacists” and the “Diabetes prevention, screening and management: A handbook for pharmacists” in Spanish (thanks to the College of Chemists, Biochemists and Pharmacists of Pichincha)
## Finances

### Balance sheet at 31 December 2022

*After appropriation of the results for 2022 (Expressed in EURO)*

<table>
<thead>
<tr>
<th>Category</th>
<th>Actuals 2022</th>
<th>Budget 2022</th>
<th>Budget vs actuals</th>
<th>Actuals 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intangible fixed assets</strong></td>
<td>2 076</td>
<td></td>
<td></td>
<td>13 746</td>
</tr>
<tr>
<td><strong>Tangible fixed assets</strong></td>
<td>535 210</td>
<td></td>
<td></td>
<td>570 104</td>
</tr>
<tr>
<td><strong>Current assets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Debtors, prepayments and accrued income</td>
<td>327 524</td>
<td>323 068</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash at bank and in hand</td>
<td>2 947 492</td>
<td>3 065 712</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td>3 265 016</td>
<td>3 388 780</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>3 802 402</td>
<td>3 973 120</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Capital and reserves</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FIP capital</td>
<td>3 228 289</td>
<td>1 294 382</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sections capital</td>
<td>813 473</td>
<td>374 157</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congress reserve</td>
<td>650 000</td>
<td>650 000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Board of Pharmaceutical Practice reserve</td>
<td>43 710</td>
<td>43 710</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Board of Pharmaceutical Sciences reserve</td>
<td>58 795</td>
<td>58 795</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reserve FIPFD</td>
<td>125 959</td>
<td>125 959</td>
<td></td>
<td></td>
</tr>
<tr>
<td>One FIP Project Fund</td>
<td>283 500</td>
<td>255 272</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total capital and reserves</strong></td>
<td>3 374 632</td>
<td>3 210 458</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Provisions</strong></td>
<td>39 751</td>
<td>42 836</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Current liabilities</strong></td>
<td>488 010</td>
<td>720 826</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total capital and reserves and liabilities</strong></td>
<td>3 802 402</td>
<td>3 973 120</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Income

<table>
<thead>
<tr>
<th>Category</th>
<th>Actuals 2022</th>
<th>Budget 2022</th>
<th>Budget vs actuals</th>
<th>Actuals 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership fees FIP (MO, AIM &amp; IM)</td>
<td>1 004 688</td>
<td>1 050 000</td>
<td>(45 312)</td>
<td>1 048 504</td>
</tr>
<tr>
<td>Congress expenses</td>
<td>933 576</td>
<td>950 000</td>
<td>(16 424)</td>
<td>913 576</td>
</tr>
<tr>
<td>Sections income</td>
<td>137 233</td>
<td>100 000</td>
<td>37 233</td>
<td>64 744</td>
</tr>
<tr>
<td>External partnerships and support</td>
<td>1 268 186</td>
<td>1 000 000</td>
<td>268 186</td>
<td>1 268 186</td>
</tr>
<tr>
<td>Other income</td>
<td>30 708</td>
<td>20 000</td>
<td>10 708</td>
<td>30 708</td>
</tr>
<tr>
<td><strong>Total income</strong></td>
<td>3 373 791</td>
<td>3 120 000</td>
<td>253 791</td>
<td>3 102 791</td>
</tr>
</tbody>
</table>

### Expenses

<table>
<thead>
<tr>
<th>Category</th>
<th>Actuals 2022</th>
<th>Budget 2022</th>
<th>Budget vs actuals</th>
<th>Actuals 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership costs</td>
<td>17 982</td>
<td>17 500</td>
<td>482</td>
<td>28 748</td>
</tr>
<tr>
<td>Personnel costs</td>
<td>1 299 725</td>
<td>1 300 000</td>
<td>(275)</td>
<td>1 012 422</td>
</tr>
<tr>
<td>Office costs</td>
<td>150 039</td>
<td>240 000</td>
<td>89 961</td>
<td>110 137</td>
</tr>
<tr>
<td>Executive Committee and Bureau meeting costs</td>
<td>25 088</td>
<td>75 000</td>
<td>(49 912)</td>
<td>9 838</td>
</tr>
<tr>
<td>Travel expenses &amp; external representation</td>
<td>11 431</td>
<td>50 000</td>
<td>(38 569)</td>
<td>986</td>
</tr>
<tr>
<td>Website and IT</td>
<td>171 704</td>
<td>171 000</td>
<td>(704)</td>
<td>1 704</td>
</tr>
<tr>
<td>GPO-Atlas</td>
<td>120 139</td>
<td>110 000</td>
<td>10 139</td>
<td>147 746</td>
</tr>
<tr>
<td>Depreciation of fixed assets</td>
<td>68 237</td>
<td>60 000</td>
<td>8 237</td>
<td>66 618</td>
</tr>
<tr>
<td>FIP Provision</td>
<td>62 012</td>
<td>70 000</td>
<td>(7 988)</td>
<td>55 660</td>
</tr>
<tr>
<td>ONE FIP Projects (incl. UNITWIN)</td>
<td>61 769</td>
<td>60 000</td>
<td>1 769</td>
<td>17 228</td>
</tr>
<tr>
<td>FIP Programmes</td>
<td>181 154</td>
<td>80 000</td>
<td>101 154</td>
<td>118 228</td>
</tr>
<tr>
<td>Congress expenses</td>
<td>700 326</td>
<td>650 000</td>
<td>50 000</td>
<td>2 236</td>
</tr>
<tr>
<td>Publication and communication costs</td>
<td>44 576</td>
<td>61 000</td>
<td>(16 424)</td>
<td>42 946</td>
</tr>
<tr>
<td>FIP Subventions</td>
<td>31 000</td>
<td>25 000</td>
<td>(5 000)</td>
<td>25 000</td>
</tr>
<tr>
<td>BPP Expenses</td>
<td>34 000</td>
<td>60 000</td>
<td>(26 000)</td>
<td>36 136</td>
</tr>
<tr>
<td>BPS Expenses</td>
<td>-</td>
<td>40 000</td>
<td>(40 000)</td>
<td>117</td>
</tr>
<tr>
<td>Sections’ operating costs</td>
<td>46 297</td>
<td>100 000</td>
<td>(53 703)</td>
<td>14 802</td>
</tr>
<tr>
<td>Academic institutional/Membership</td>
<td>4 356</td>
<td>30 000</td>
<td>(25 644)</td>
<td>13 866</td>
</tr>
<tr>
<td>Pharmacy Education journal &amp; FIP Hub</td>
<td>66 171</td>
<td>50 000</td>
<td>16 171</td>
<td>59 330</td>
</tr>
<tr>
<td>FIPED expenses</td>
<td>31 887</td>
<td>25 000</td>
<td>6 887</td>
<td>30 371</td>
</tr>
<tr>
<td>Maintenance Fund</td>
<td>15 000</td>
<td>15 000</td>
<td>-</td>
<td>15 000</td>
</tr>
<tr>
<td>Members &amp; Regional engagement</td>
<td>65 248</td>
<td>65 000</td>
<td>248</td>
<td>20 204</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td>3 188 937</td>
<td>3 252 000</td>
<td>(63 063)</td>
<td>2 102 710</td>
</tr>
</tbody>
</table>

**Operating result** | 184 854 | (122 000) | 306 854 | 160 065 |

**Financial result** | (120 160) | 5 000 | (125 660) | 38 759 |

**Net result before appropriation** | 64 574 | (127 000) | 191 574 | 198 824 |

### Appropriation of the result, (from/to):

<table>
<thead>
<tr>
<th>Category</th>
<th>From/to</th>
</tr>
</thead>
<tbody>
<tr>
<td>BPP general reserves</td>
<td>-</td>
</tr>
<tr>
<td>BPS general reserves</td>
<td>-</td>
</tr>
<tr>
<td>Sections capital</td>
<td>-</td>
</tr>
<tr>
<td>Reserve FIPFD</td>
<td>-</td>
</tr>
<tr>
<td>One FIP Project Fund</td>
<td>(61 769)</td>
</tr>
<tr>
<td>FIP capital</td>
<td>(144 200)</td>
</tr>
<tr>
<td><strong>Total appropriated</strong></td>
<td>64 574</td>
</tr>
</tbody>
</table>